• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

重组人腺病毒-p53治疗宫颈癌的Meta分析

Recombinant Human Adenovirus-p53 Therapy for the Treatment of Cervical Cancer: A Meta-Analysis.

作者信息

Guo Yaru, Chen Jiuzhou, Zhang Xiwen, Fang Miao, Xu Mingna, Zhang Longzhen, Rao Enyu, Xin Yong

机构信息

Department of Radiation, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Cancer Institute, Xuzhou Medical University, Xuzhou, China.

出版信息

Front Oncol. 2021 Oct 18;11:748681. doi: 10.3389/fonc.2021.748681. eCollection 2021.

DOI:10.3389/fonc.2021.748681
PMID:34733786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8558497/
Abstract

OBJECTIVES

To evaluate the clinical curative effects and toxicity of recombinant human adenovirus-p53 injection (rAd-p53) plus chemotherapy (CT), radiotherapy (RT), or concurrent chemoradiotherapy (CRT) for the treatment of cervical cancer.

METHODS

We identified 14 eligible studies in the PubMed, Web of Science, Cochrane Library, Embase, CNKI, Wangfangdate, CBM, and VIP databases from their inception to May 2021 and performed meta-analyses using RevMan version 5.3.

RESULTS

This analysis included 14 studies involving 737 patients. The results of the meta-analysis results showed significantly improved complete remission (odds ratio [OR] = 2.54, 95% confidence interval [CI]: 1.74-3.70, < 0.00001), partial remission (OR = 1.56, 95% CI: 1.14-2.14, = 0.006), and object response (OR = 4.47, 95% CI: 3.02-6.60, < 0.00001) rates in the rAd-p53 combination therapy group compared to those in the CT/RT/CRT group. The results of subgroup analyses of CT/RT/CRT were consistent with the overall results. Regarding the incidence of adverse reactions, only the occurrence rate of fever (OR = 18.21, 95% CI: 10.54-31.47, < 0.00001) in the rAd-p53 combination group was higher than that in the CT/RT/CRT group. No other significant differences were observed in other adverse reactions.

CONCLUSION

RAd-p53 combined with CT/RT/CRT for the treatment of cervical cancer showed significant advantages in efficacy and safety compared to those in the CT/RT/CRT group. Therefore, rAd-p53 has great potential as an effective therapy for cervical cancer.

SYSTEMATIC REVIEW REGISTRATION

https://inplasy.com/inplasy-2021-5-0058/.

摘要

目的

评估重组人腺病毒-p53注射液（rAd-p53）联合化疗（CT）、放疗（RT）或同步放化疗（CRT）治疗宫颈癌的临床疗效及毒性。

方法

我们在PubMed、Web of Science、Cochrane图书馆、Embase、中国知网、万方数据、中国生物医学文献数据库和维普数据库中检索了从建库至2021年5月的14项符合条件的研究，并使用RevMan 5.3软件进行荟萃分析。

结果

该分析纳入了14项研究，共737例患者。荟萃分析结果显示，与CT/RT/CRT组相比，rAd-p53联合治疗组的完全缓解率（优势比[OR]=2.54，95%置信区间[CI]：1.74-3.70，P<0.00001）、部分缓解率（OR=1.56，95%CI：1.14-2.14，P=0.006）和客观缓解率（OR=4.47，95%CI：3.02-6.60，P<0.00001）均显著提高。CT/RT/CRT亚组分析结果与总体结果一致。关于不良反应的发生率，仅rAd-p53联合组的发热发生率（OR=18.21，95%CI：10.54-31.47，P<0.00001）高于CT/RT/CRT组。在其他不良反应方面未观察到其他显著差异。

结论

与CT/RT/CRT组相比，rAd-p53联合CT/RT/CRT治疗宫颈癌在疗效和安全性方面具有显著优势。因此，rAd-p53作为宫颈癌的有效治疗方法具有巨大潜力。

系统评价注册

https://inplasy.com/inplasy-2021-5-0058/ 。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/2191cd6d42c0/fonc-11-748681-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/d6be448cc11e/fonc-11-748681-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/1e7bd793226a/fonc-11-748681-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/dac544d61787/fonc-11-748681-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/b259968e8464/fonc-11-748681-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/97da60960f44/fonc-11-748681-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/b5f225565e4e/fonc-11-748681-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/607a73f957dc/fonc-11-748681-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/9ffde67f875d/fonc-11-748681-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/da5d97cd78c0/fonc-11-748681-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/e0fd582496a8/fonc-11-748681-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/2191cd6d42c0/fonc-11-748681-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/d6be448cc11e/fonc-11-748681-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/1e7bd793226a/fonc-11-748681-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/dac544d61787/fonc-11-748681-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/b259968e8464/fonc-11-748681-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/97da60960f44/fonc-11-748681-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/b5f225565e4e/fonc-11-748681-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/607a73f957dc/fonc-11-748681-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/9ffde67f875d/fonc-11-748681-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/da5d97cd78c0/fonc-11-748681-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/e0fd582496a8/fonc-11-748681-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/8558497/2191cd6d42c0/fonc-11-748681-g011.jpg

相似文献

1
Recombinant Human Adenovirus-p53 Therapy for the Treatment of Cervical Cancer: A Meta-Analysis.重组人腺病毒-p53治疗宫颈癌的Meta分析
Front Oncol. 2021 Oct 18;11:748681. doi: 10.3389/fonc.2021.748681. eCollection 2021.
2
Recombinant human adenovirus p53 combined with transcatheter arterial chemoembolization for liver cancer: A meta-analysis.重组人腺病毒 p53 联合经导管动脉化疗栓塞治疗肝癌的Meta 分析。
PLoS One. 2023 Dec 21;18(12):e0295323. doi: 10.1371/journal.pone.0295323. eCollection 2023.
3
Efficacy and Safety of Recombinant Human p53 Adenovirus Injection Combined with Radiotherapy or Concurrent Chemoradiotherapy in the Treatment of Cervical Cancer: A Systematic Review and Meta-analysis.重组人p53腺病毒注射液联合放疗或同步放化疗治疗宫颈癌的疗效与安全性：一项系统评价和Meta分析
Altern Ther Health Med. 2024 Sep;30(9):78-84.
4
Recombinant human adenovirus-p53 therapy for the treatment of nasopharyngeal carcinoma: a meta-analysis.重组人腺病毒-p53治疗鼻咽癌的Meta分析
Springerplus. 2016 Oct 27;5(1):1885. doi: 10.1186/s40064-016-3574-6. eCollection 2016.
5
Effect and Safety of Recombinant Adenovirus-p53 Transfer Combined with Radiotherapy on Long-Term Survival of Locally Advanced Cervical Cancer.重组腺病毒-p53转染联合放疗对局部晚期宫颈癌长期生存的疗效及安全性
Hum Gene Ther. 2016 Dec;27(12):1008-1014. doi: 10.1089/hum.2016.043. Epub 2016 Aug 30.
6
Efficacy and safety of recombinant human adenovirus p53 combined with chemoradiotherapy in the treatment of recurrent nasopharyngeal carcinoma.重组人腺病毒p53联合放化疗治疗复发性鼻咽癌的疗效与安全性
Anticancer Drugs. 2017 Feb;28(2):230-236. doi: 10.1097/CAD.0000000000000448.
7
Chemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis.同步放化疗联合区域热疗治疗晚期食管癌：系统评价与Meta分析
J Clin Pharm Ther. 2017 Apr;42(2):155-164. doi: 10.1111/jcpt.12498. Epub 2017 Jan 25.
8
Recombinant adenovirus-p53 enhances the therapeutic effect of surgery and chemoradiotherapy combination in hypopharyngeal squamous cell carcinomas patients.重组腺病毒-p53增强了下咽鳞状细胞癌患者手术与放化疗联合治疗的效果。
Medicine (Baltimore). 2018 Aug;97(35):e12193. doi: 10.1097/MD.0000000000012193.
9
Adjuvant chemoradiotherapy versus radiotherapy in cervical cancer patients with intermediate-risk factors: A systematic review and meta-analysis.辅助放化疗与单纯放疗治疗中危因素宫颈癌患者的疗效比较：一项系统评价和荟萃分析。
Eur J Obstet Gynecol Reprod Biol. 2019 Jul;238:1-6. doi: 10.1016/j.ejogrb.2019.04.039. Epub 2019 May 4.
10
Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis.辅助放化疗与单纯放疗治疗高危子宫内膜癌的疗效比较：系统评价与荟萃分析。
Gynecol Oncol. 2018 Jun;149(3):612-619. doi: 10.1016/j.ygyno.2018.03.004. Epub 2018 Mar 9.

引用本文的文献

1
Efficacy analysis of targeted P53 therapy in solid tumors.实体瘤中靶向P53治疗的疗效分析
Med Oncol. 2025 Jul 22;42(8):360. doi: 10.1007/s12032-025-02930-y.
2
Adenoviral Therapy for Cervical Cancer: From Targeted Modification to Immunotherapy.腺病毒疗法治疗宫颈癌：从靶向修饰到免疫治疗
Anticancer Agents Med Chem. 2025;25(14):967-977. doi: 10.2174/0118715206338559241112060553.
3
Towards a 'clicked' PSMA targeting gene delivery bioconjugate-polyplex for prostate cancer.迈向用于前列腺癌的“点击式”靶向前列腺特异性膜抗原（PSMA）的基因递送生物共轭物-多聚体

本文引用的文献

1
Therapeutic potential of p53 reactivation in cervical cancer.p53 再激活在宫颈癌治疗中的潜力。
Crit Rev Oncol Hematol. 2021 Jan;157:103182. doi: 10.1016/j.critrevonc.2020.103182. Epub 2020 Nov 24.
2
E2F1/2/7/8 as independent indicators of survival in patients with cervical squamous cell carcinoma.E2F1/2/7/8作为宫颈鳞状细胞癌患者生存的独立指标。
Cancer Cell Int. 2020 Oct 12;20:500. doi: 10.1186/s12935-020-01594-0. eCollection 2020.
3
Combined effect of recombinant human adenovirus p53 and curcumin in the treatment of liver cancer.
RSC Adv. 2024 Jul 29;14(33):23796-23801. doi: 10.1039/d4ra03640a. eCollection 2024 Jul 26.
4
Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology.20年的健择®重组人5型腺病毒载体抑癌基因（rAd-p53）癌症基因治疗：个性化肿瘤学时代的首个同类人癌症基因治疗。
Genes Dis. 2023 Oct 31;11(4):101155. doi: 10.1016/j.gendis.2023.101155. eCollection 2024 Jul.
5
A hidden translatome in tumors-the coding lncRNAs.肿瘤中的隐藏转录组——编码长链非编码RNA
Sci China Life Sci. 2023 Dec;66(12):2755-2772. doi: 10.1007/s11427-022-2289-6. Epub 2023 May 5.
重组人腺病毒 p53 与姜黄素联合治疗肝癌的效果
Exp Ther Med. 2020 Nov;20(5):18. doi: 10.3892/etm.2020.9145. Epub 2020 Aug 26.
4
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.HPV 疫苗接种和宫颈筛查对宫颈癌消除的影响：78 个低收入和中低收入国家的比较建模分析。
Lancet. 2020 Feb 22;395(10224):575-590. doi: 10.1016/S0140-6736(20)30068-4. Epub 2020 Jan 30.
5
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.2018 年宫颈癌发病率和死亡率的估计：全球分析。
Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Epub 2019 Dec 4.
6
Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.顺铂和吉西他滨新辅助化疗联合放化疗对比单纯放化疗治疗局部晚期宫颈癌的随机 II 期临床试验。
J Clin Oncol. 2019 Nov 20;37(33):3124-3131. doi: 10.1200/JCO.19.00674. Epub 2019 Aug 26.
7
Sensitivity of ASPP and P-gp to neoadjuvant chemotherapy combined with gene therapy in locally advanced cervical cancer.ASPP和P-糖蛋白对局部晚期宫颈癌新辅助化疗联合基因治疗的敏感性。
J BUON. 2019 May-Jun;24(3):967-974.
8
Therapeutic Delivery of miR-29b Enhances Radiosensitivity in Cervical Cancer.miR-29b 的治疗性递送增强宫颈癌的放射敏感性。
Mol Ther. 2019 Jun 5;27(6):1183-1194. doi: 10.1016/j.ymthe.2019.03.020. Epub 2019 Apr 11.
9
Cervical cancer.宫颈癌。
Lancet. 2019 Jan 12;393(10167):169-182. doi: 10.1016/S0140-6736(18)32470-X.
10
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.微创与经腹根治性子宫切除术治疗宫颈癌的比较。
N Engl J Med. 2018 Nov 15;379(20):1895-1904. doi: 10.1056/NEJMoa1806395. Epub 2018 Oct 31.